fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Trospium chloride

All products: Limited Use (codes 290)

Mar-Trospium · DIN 02488353 · 20 mg · tablet

Limited Use, Reason for Use code 290 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Mar-Trospium · DIN 02488353 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2019-08-30 Health Canada: Marketed since 2019-06-21 · brand MAR-TROSPIUM · ATC G04BD09 TROSPIUM · form Tablet · route Oral · ingredients TROSPIUM CHLORIDE 20 MG · company Marcan pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Mar-Trospium: Formulary list price $0.41 per unit (the source does not state the unit; exact figure $0.4072). What the ministry pays, not the patient.

Ministry pays: $0.4072 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02488353)

Source record
DIN 02488353: Mar-Trospium Raw flags: sec12=Y, sec3=Y Item: 920000642; group id 975; item number 2311; lccId 00217; manufacturer id MAR Source form: Tab; strength: 20mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $0.4072; ministry $0.4072 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02488353 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97846
Interchangeable products
Jamp Trospium · DIN 02506661 · $0.4072 Trosec · DIN 02275066 · not recorded
Shortage status: not checked (no credentials)

Other products in the same Health Canada class (G04B, G04BD): coverage varies; not interchangeable

  • Darifenacin (Enablex): limited Use 290
  • Solifenacin (Vesicare): limited Use 290
  • Tolterodine l (Detrol LA): limited Use 290
  • Sildenafil (Revatio): not a benefit
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM, RISPERIDONE Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

DARIFENACIN

· 6 products · Limited Use, codes 290 · strengths: 7.5mg, 15mg · ER Tab

SOLIFENACIN SUCCINATE

· 30 products · Limited Use, codes 290 · strengths: 5mg, 10mg · Tab

TOLTERODINE L-TARTRATE

· 12 products · Limited Use, codes 290 · strengths: 2mg, 4mg, 1mg · SR Cap, Tab

SILDENAFIL

· 47 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 20mg, 25mg, 50mg, 100mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 92:00 and 78 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Mar-Trospium (trospium chloride) is indicated for:  the treatment of overactive bladder with symptoms of urge or mixed urinary incontinence, urgency, and urinary frequency. https://pdf.hres.ca/dpd_pm/00051102.PDF PM date: not printed or not captured Source product: MAR-TROSPIUM; DIN 02488353; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.